Treatment of patients with myelodysplastic syndrome (MDS) with lenalidomide in clinical routine in Austria

Publication date: Available online 5 August 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): G. Aschauer, R. Greil, W. Linkesch, T. Nösslinger, R. Stauder, S. Burgstaller, M. Fiegl, M. Fridrik, M. Girschikofsky, F. Keil, A.L. Petzer Lenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q-. The present evaluation aims to describe the characteristics and outcomes of low-risk MDS patients treated with lenalidomide in Austria. For this retrospective, multicentre, observational analysis of MDS patients who received lenalidomide, data were collected at various hospitals in Austria over a period of 3 years. MDS classification, previous and current MDS therapies, outcome and safety of lenalidomide were evaluated. Fourty-six percent of the patients (n=23) suffered from a 5q- syndrome while 12% (n=6) showed 5q- plus additional aberrations or isolated 5q- but ≥5% blasts in the bone marrow (10%, n=5). The remaining 32% of patients (n=16) had MDS with other WHO classifications. Seventy percent belonged to lower International Prognostic Scoring System (IPSS) risk classes. Sixteen centres participated, involving a total of 50 patients. Most frequently used lenalidomide doses were 10 mg and 5 mg on days 1-21 of a 28-day cycle. Seventy-five percent of the patients received 11 months of treatment, with a median therapy period of 3.5 months, median follow-up was 3.9 months (range, 0-...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research